Gleevec, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML ). In June 2006, a Phase I clinical trial found gleevec has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment.
Gleevec is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Imprints
Drug: Gleevec
Strength: 400 Mg
Pill Imprint: 400 SL SL
Color: Orange
Shape: Elliptical / Oval
View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.